surmount-1 trial tirzepatide non-diabetic obesity weight loss nondiabetic For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults Tirzepatide after intensive lifestyle intervention – Tirzepatide as Compared with Semaglutide

Most users report mild, transient cardiovascular effects during initial use, with some experiencing temporary warmth or flushing from vasodilation

This helps lower both fasting and after-meal glucose levels in a more physiologic way

Important Note: It's best to work with a registered dietitian or nutritionist to create a personalized meal plan that meets your individual needs and preferences

This personalized support ensures you can continue your weight management journey comfortably and effectively

The MHRA approved the Wegovy pill in June 2026, the first weight-loss tablet licensed in the UK, and it reached private providers, including Second Nature, in July 2026

If your Cigna plan does not cover Zepbound, you may still be able to save on the price of the medication by using the Zepbound Savings Card or pharmacy discounts